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Antibiotics are often differentiated by their ability to either inhibit growth (bacteriostatic) or 47 to kill bacteria (bactericidal). The exact differentiation of antibiotics into these broad 48 categories likely depends on the species and the specific growth environment in which 49 antibiotic susceptibility is tested (1, 2). To optimize therapy, it is essential to gain a 50 comprehensive understanding of the variable factors that modulate bacterial susceptibility 51 to antibiotics. For example, the -lactams (penicillins, cephalosporins, cephamycins, 52 carbapenems, and the monobactam aztreonam), which are among the most powerful 53 agents in our antibiotic armamentarium, prevent and/or corrupt proper cell wall 54 (peptidoglycan) assembly (3, 4) . Consequently, these agents typically induce cell death 55 and lysis in susceptible bacteria at least during rapid growth in vitro (3, 4) . However, in 56 vivo -lactams often fail to eradicate an infection caused by susceptible (i.e., non-57 resistant) organisms (5-7). This paradox can, in part, be explained by the presence of 58 dormant persister cells, a small subpopulation that resists killing by antibiotics that require 59 cellular activity for their lethal action (8-10). However, specimens obtained from patients 60 treated with -lactam antibiotics have been reported to contain spheroplasts, bacterial 61 cells that lack a cell wall (11)(3), and clinical isolates are often highly tolerant to -lactam 62 antibiotics at frequencies that cannot solely be explained by invoking rare persister cells 63 (4,5)(12). Spheroplast formation suggests that in these bacteria the antibiotic is effective 64 in inhibiting cell wall synthesis, demonstrating that some bacteria survive antibiotic 65 exposure in forms that are neither dormant nor resistant. We and others have previously 66
shown that two important Gram-negative pathogens, Vibrio cholerae and Pseudomonas 67 aeruginosa, form viable, non-dividing spheroplasts when exposed to inhibitors of cell wallsynthesis (6,7)(13). Spheroplasts readily revert to rod-shape and exponential growth, 69 suggesting these cells might promote re-infection upon discontinuation of antibiotic 70 therapy. Successful recovery of V. cholerae spheroplasts requires the cell wall stress 71 sensing two-component system VxrAB (also known as WigKR (14, 15)), cell wall 72 synthesis functions and the general envelope stress-sensing alternative sigma factor 73
RpoE (16). 74 75
Spheroplast formation is reminiscent of so-called Gram-positive "L-forms": irregularly 76 dividing, cell wall-less cells surrounded only by their cytoplasmic membranes (9) . 77
However, in striking contrast to L-forms, Gram-negative spheroplasts do not divide in the 78 presence of antibiotic (13, 17) . Division through an L-form-like mechanism is likely 79 prevented by the presence of their strong outer membrane (OM) which exhibits almost 80 cell wall-like mechanical properties (18). Indeed, dividing L-forms of the Gram-negative 81 model organism Escherichia coli can be generated by inhibiting cell wall synthesis in 82 osmostabilized growth medium, which causes the cytoplasm to "escape" its OM shell 83
(19). 84 85
While L-form formation has been implicated as a mechanism of antibiotic resistance in 86
Gram-positive bacteria (11), it is unclear whether spheroplast formation represents a 87 general strategy elicited by Gram-negative bacteria to tolerate cell wall synthesis 88 inhibitors such as the -lactams. Here, we have tested a collection of well-characterized 89
American Type Culture Collection (ATCC) and clinical Gram-negative isolates (Table 1)  90 for their ability to tolerate exposure to the carbapenem antibiotic meropenem. We findthat, with the notable exception of E. coli, all isolates formed cell wall-deficient 92 spheroplasts upon exposure to meropenem, and these spheroplasts were able to fully 93 recover to rod-shape and exponential growth upon removal of meropenem, both in a 94 laboratory medium and in human serum. Our data suggest that spheroplast-mediated 95 carbapenem tolerance is prevalent in clinically significant Gram-negative pathogens, but 96 rare or absent in the E. coli isolates tested herein. Our results suggest that measures of 97 antibiotic susceptibility and ultimately treatment outcome could consider more nuanced 98 responses in diverse, clinically-relevant Gram-negative pathogens. 99
100
Results
101
Tolerance to Meropenem Varies Across Gram-Negative Clinical Isolates 102
Spheroplast-mediated -lactam tolerance might be an underappreciated menace in the 103 clinical setting. To test how widespread the ability to tolerate cell wall acting antibiotics is 104 in clinical isolates, we assayed a panel of clinical isolates representative of significant 105
Gram-negative pathogens of the family Enterobacteriaceae: E. coli, including 106
Enterohemorrhagic E. coli (EHEC), Enterobacter cloacae, Klebsiella aerogenes (formerly 107
Enterobacter aerogenes), and Klebsiella pneumoniae. We also tested organisms known 108 to form spheroplasts under some conditions: V. cholerae and P. aeruginosa. As a 109
representative -lactam, we used the carbapenem meropenem. We chose meropenem 110 due to its importance as a potent, broad-spectrum agent (20, 21) , and also because in 111 clinical practice, especially in the setting of multi-drug resistance, it is often used against 112 members of our isolate panel (20, 22) . 113
We conducted time-dependent killing experiments measuring both colony forming units 115 (cfu/ml) and optical density (OD600 Among the susceptible/non-resistant, non-carbapenemase producing isolates, killing and 134 optical density dynamics varied widely between species and even isolates within the 135 same species (e.g., E. cloacae WCM0001 versus E. cloacae ARB0008) (Fig. 1) . 136
Interestingly, both in lysis behavior and survival, E. coli was considerably less tolerantthan all other tested organisms (Fig. 1) . While killing efficiency after 6 hours of 138 meropenem exposure generally ranged from ~ 5 to10-fold killing (V. cholerae N16961, P. 139 aeruginosa PA14, E. cloacae WCM0001, E. cloacae ATCC 13047) to ~5,000-fold killing 140 (K. aerogenes WCM0001, E. cloacae ARB0008, K. pneumoniae WCM0001 and 141 WCM0002), both E. coli isolates tested were almost completely eradicated by 142 meropenem (~10 8 -fold killing) (Fig. 1, S1 -S2 ). In contrast, almost all isolates grew well 143 in the absence of meropenem, except for both isolates of P. aeruginosa, which exhibited 144 slower growth in BHI+ compared to the other isolates (Fig. S3) . Interestingly, E. cloacae 145 ARB0008 had a higher meropenem MIC than the other E. cloacae isolates, but was 146 among the isolates with the highest degree of killing. This observation suggests that 147 susceptibility (i.e., differences in MIC values) might not necessarily correlate with 148 tolerance, i.e., the degree of killing. 149 150 Similar to V. cholerae and P. aeruginosa (Fig. S1 -S2 and (13)), survival of meropenem-151 treated cells often coincided with a substantial increase in OD600 (while cfu/mL stayed the 152 same or decreased) (Fig. 1) KPC positive isolates increased in both OD600 and cfu/ml during meropenem exposure 159 (Fig. S4) . 160
In V. cholerae and P. aeruginosa, -lactam tolerant cells are cell wall-less, metabolically 163 active spheroplasts. In principle, the moderate to high level tolerance we observed in our 164 experiments could also be a consequence of unusually high levels of dormant persister 165 cells in these clinical isolates due to a prolonged lag phase (27) emerging from stationary 166 phase. To distinguish between these two possibilities, we withdrew samples at various 167 time points following exposure to meropenem and imaged them. Dormant persister cells 168 remain rod-shaped in the presence of cell wall acting antibiotics, since these cells prevent 169
antibiotic damage completely through their lack of growth (28, 29) . Visual examination 170 revealed that, comparable to previous observations in V. cholerae and P. aeruginosa 171 (6,7), the tolerant populations of almost all isolates consisted exclusively of spherical cells 172 ( Fig. 2 and S1-S2, S5 -S8). The notable exception were the two E. coli isolates; while 173 some spherical cells could be observed after short exposure periods in both tested 174 isolates, after 6 hours of antibiotic exposure only cell debris was observed ( Fig. 2 and  175 
Fig. S9).
In contrast to those cultures treated with meropenem, untreated bacteria 176 retained rod-shape in BHI+ (Fig. S10) ; similar to the conspecific, but KPC positive, 177
isolates with or without meropenem treatment (Fig. S11) . 178
179
We next used the cell wall stain 7-hydroxycoumarin-amino-D-Alanine (HADA) (30) to test 180 whether the observed spheroplasts were able to survive meropenem exposure by 181 synthesizing cell wall material in a meropenem-insensitive manner, or by being able to 182 sustain structural integrity in the absence of the cell wall. Indeed, osmotically stable, cellwall-containing spherical cells that resemble spheroplasts can be observed in E. coli 184 when the elongation-specific class B penicillin-binding protein (PBP) 2 is inhibited (31). 185
Addition of HADA revealed little to no detectable cell wall material in meropenem-treated 186 cells, but, consistent with published data from E. coli, did result in strong staining of PBP2-187 inhibited (i.e., mecillinam-treated) cells (Fig. 3) . The lack of detectable cell wall material 188 in meropenem-treated cells, combined with their rapid loss of cell shape, suggests these 189 spheroplasts maintain structural integrity through their outer membrane, rather than a 190 reorganized cell wall. This is in line with the recent realization that the Gram-negative OM 191 has a higher than appreciated mechanical load capacity (12). Lastly, loss of the cell wall 192 is typically associated with inhibition of multiple PBPs that include class A PBPs (32) . 193 Meropenem has a high affinity for PBP2 (33) some spheroplasts from all isolates were able to recover to rod-shape (Fig. 4, Fig. S1 -203 S2, S5-S8); albeit with different dynamics (cf. E. cloacae WCM0001 vs. K. aerogenes 204 WCM0001). The recovery process often included rapid division (e.g., 25 min after 205 removing the antibiotic in K. pneumoniae WCM0001) as spherical cells, resulting in two 206 half-spheroplasts that then increasingly approximated rod-shape during subsequent 207 division events. Taken together, our results suggest that the high tolerance levels 208 observed for the Gram-negative pathogens tested here are not mediated by dormancy, 209 or prolonged lag phase after stationary phase, but rather by the ability to survive for 210 extended time periods without a structurally sound cell wall. 211
212
Quantification of Gram-Negative Tolerance: The Weaver Score 213
Since our observational data suggested variations in tolerance levels, we sought to 214 quantify the ability to survive and maintain cellular structural integrity during exposure to 215 meropenem. Assays to determine tolerance levels based on killing dynamics have been 216 developed (10, 36); however, we chose to incorporate both cfu/mL and OD600 217 measurements in our tolerance score. In principle, both cfu/mL (viability) and OD600 218 measurements can report on tolerance to -lactam antibiotics as both are indicators of 219 the bacterial cell's ability to resist antibiotic-induced lysis. We argue that cell lysis and 220 death can in principle be separable contributors to tolerance. We cannot exclude, for 221 instance, that a significant proportion of antibiotic-damaged spheroplasts die only upon 222 plating on solid media, a condition that results in oxidative stress (37). An isolate that 223 exhibits a significant decrease in viability after exposure to a -lactam but does not lyse 224 would likely be given a low tolerance designator if cfu/mL only were considered. However, 225 the spheroplasts that do not recover on plates might recover at a high rate under 226 circumstances where cells are not plated following exposure (e.g., in the host). Thus, we 227 consider that OD600 measurements (in conjunction with cfu/mL) hold informative value for 228 tolerance measurements. We developed a meropenem survival/integrity score, thetreatment over initial cfu/mL) with the fraction of OD600 readings (OD600 reading after 6 231 hours of treatment over initial OD600 reading) (see Methods for details). We were thus 232 able to generate a single value for overall tolerance that considers both parameters of the 233 culture: lysis behavior and plating defect. According to this score, V. cholerae N16961, P. 234 aeruginosa PA14 and the E. cloacae isolates WCM0001 and ATCC 13047 emerged as 235 the most tolerant of the susceptible/non-resistant, non-carbapenemase producing 236 organisms, while both tested K. pneumoniae and both K. aerogenes isolates exhibited 237 intermediate tolerance, and E. coli ranked the lowest (Fig. 5) . Consistent with their ability 238 to grow in the presence of meropenem, the KPC-producing isolates scored the highest. 239 240
Spheroplast-formation in human serum 241
To evaluate tolerance in an environment more reminiscent of growth in the human host, 242
we performed killing experiments in human serum. Colony forming units (serum growth 243 medium is incompatible with OD measurements) were measured after six hours of 244 incubation with or without meropenem (Fig. 6 ) and cells were observed directly for 245 spheroplast-formation. All isolates grew in serum growth medium (Fig. 6B) , but compared 246 to BHI+, killing by meropenem was reduced for some isolates. K. aerogenes ARB0007 247 and K. pneumoniae WCM0001 were almost completely tolerant with only a ~5-fold 248 decrease in viability over the 6 hour period, compared to the 10 to 100-fold killing that 249 occurs in BHI+ with these isolates. Conversely, E. cloacae WCM0001 was killed at a 250 higher rate in human serum than in BHI+. However, spheroplasts were observed for all 251 isolates, except for E. coli, and recovery to rod-shape morphology and exponential growth 252 upon removal of the antibiotic by addition of NDM was efficient (Fig. 6C) . Taken together, 253 these data suggest that the degree of tolerance is growth-medium specific (though E. coli 254 was still the least tolerant), but that spheroplast formation as a means of tolerating 255 exposure to meropenem is conserved across bacteria and conditions tested here. 256 257
Discussion
258
In contrast to antibiotic resistance (the ability to grow in the presence of antibiotics), the 259 phenomenon of antibiotic tolerance (the ability to resist killing by bactericidal antibiotics 260 for extended time periods) remains understudied. While a lot of effort has been directed 261 at understanding persister cells (9) (multidrug tolerant, dormant or near-dormant 262 phenotypic variants produced as a small fraction of bacterial populations), it is unclear 263 what other strategies might exist among bacteria to resist killing by ordinarily bactericidal 264 antibiotics. We and others have previously described a tolerance mechanism (via 265 formation of stable spheroplasts) by which Gram-negative bacteria are able to survive the 266 normally lethal event of cell wall removal that is caused by exposure to -lactam 267 antibiotics and other inhibitors of cell wall synthesis (13, 14, 16, 17) . Cell wall-less Gram-268 negative spheroplasts are formed by the majority population, are not dormant (i.e., not 269 persisters), and presumably rely on their strong OM to maintain structural integrity (16) . 270
Here, we show that this phenomenon is more widespread than previously recognized. 271
Gram-negative clinical isolates that are susceptible/non-resistant to meropenem as 272 determined using conventional MIC-based methods failed to be eradicated at appreciable 273 levels of antibiotic, and surviving cells were spheroplasts devoid of detectable cell wall 274 material. Our data raise the possibility that rapid death and lysis of majority populationsafter -lactam therapy might be the exception, not the norm, in clinical practice. Therefore 276 in addition to persister formation (8-10, 38), heteroresistance (39), and overt resistance 277 (20), these data highlight a fourth potential mechanism for -lactam therapy treatment 278
failure. 279 280
Importantly, spheroplast-like structures have been isolated from patients that were 281 infected with Gram-negative pathogens and treated with -lactam antibiotics (3), raising 282 the possibility that these cells are able to survive without a cell wall in the human host. 283
Consistent with this idea, we have observed spheroplast formation in our collection of 284
Enterobacteriaceae during exposure to meropenem in human serum growth medium. 285
Therefore, we consider it likely that spheroplasts, similar to persisters, can be responsible 286 for recalcitrant infections. Indeed, herein, we present the first evidence that carbapenem-287 induced spheroplasts in significant pathogens of the family Enterobacteriaceae can 288 readily revert to rod-shape and exponential growth upon removal of carbapenem. While 289 in some previous studies spheroplast formation has been noted (3,13)(40, 41), evidence 290 of spheroplast recovery (i.e., reversion to rod-shaped, exponentially growing cells) was 291
lacking. As such, spheroplast formation has not been incorporated into models of 292 antibiotic susceptibility, particularly in the host. In addition, Gram-negative bacteria 293 typically used as model organisms in the laboratory lyse upon exposure to -lactams in 294 standard laboratory media (e.g., LB broth) (42), creating the potential misconception that 295 the standard response to inhibition of cell wall synthesis is lysis. Future experiments will 296 determine if spheroplasts that are able to revert to a growing population are also observed 297 However, unlike L-forms, Gram-negative spheroplasts fail to proliferate in the presence 313 of antibiotics and only recover to rod-shape and exponential growth when the antibiotic is 314 removed. L-form cell division relies on membrane lipid overproduction and subsequent 315 stochastic blebbing (43). We speculate that in Gram-negative spheroplasts, L-form-like 316 proliferation is prevented due to their cytoplasmic membranes being confined by their 317 rigid OMs, thus preventing division through membrane blebs. 318
In summary, our work demonstrates that the ability to survive bactericidal -lactam 320 antibiotics does not solely rely on classical resistance or dormancy, but instead could also 321 be dependent upon an intrinsic tolerance mechanism in Gram-negative pathogens that 322 are otherwise fully susceptible to the damage induced by cell wall acting agents. Rather 323 than preventing harmful effects of antibiotics (as in resistance and dormancy), these 324 tolerant spheroplasts survive by circumventing the essentiality of the antibiotic's main 325 target, the cell wall. Our observations underscore the necessity of studying clinical 326 isolates to gain a more complete understanding of the complex processes underlying the 327 
Material and Methods
344
Chemicals, media and growth conditions 345
Meropenem (TCI chemicals, Portland, OR) was formulated as a 10 mg/mL stock solution 346 in distilled water and stored at -20˚C. BHI+ medium (per liter: 17.5 g brain heart infusion 347 from solids, 10.0 g pancreatic digest of gelatin, 2.0 g dextrose, 5.0 g sodium chloride, 2.5 348 g disodium phosphate, 15.0 μg/mL hemin, 15.0 μg/mL NAD+) was purchased from RPI 349 
Bacterial isolates 357
Bacterial isolates are summarized in Table 1 . Clinical isolates were identified to the 358 species or complex level (in the case of E. cloacae) using matrix-assisted laser 359 desorption/ionization-time of flight mass spectrometry (MALDI Biotyper, Bruker Daltonics, 360
Inc., Billerica, MA) according to the manufacturer's instructions. Meropenem AST ( Table  361 1) was performed for all isolates using gradient diffusion (Etest, bioMérieux, Inc., Durham, 362 NC) according to the manufacturer's instructions on both MHA and BHI+ agar (i.e., solid 363 media). Each day of testing, quality control testing of the Etest strips was performed on 364 both MHA and BHI+ with E. coli ATCC 25922. In all cases, quality control passed on both 365 MHA and BHI+ agar. The resultant AST data obtained with MHA was interpreted using 366 the CLSI M100-S29 (Enterobacteriaceae and P. aeruginosa) and M45 (V. cholerae) 367 documents (24, 25 
Time-dependent killing experiments 381
Overnight cultures of each isolate were grown at 37˚C in liquid BHI+ medium and the 382 following day diluted 1:10 in fresh, pre-warmed BHI+ medium containing a final 383 concentration of 10 µg/mL meropenem. At each time-point, samples were diluted five-384 fold in blank medium and OD600 was measured. At the same time point, viable cell counts 385 were also assessed by 10-fold serially diluting cells in BHI+ and spot-plating 10 µL of 386 each dilution on BHI+ agar plates. Colonies were counted after 24 hours growth at 30˚C.
Images were taken by placing cells on BHI+ agarose pads (0.8 % [w/v] agarose). Cells 388
were concentrated by centrifugation (8,000 x g, 5 min) where necessary. 389 390 391
Weaver tolerance score 392
The tolerance score was calculated from measurements of OD600 and cfu/mL after 6 393 hours of exposure to meropenem. The score was calculated as (ODt6 /ODt0) × (cfu/mLt6 394 /cfu/mLt0); i.e., OD-fold change multiplied with survival fraction. 395 396
Time-dependent killing assays in human serum 397
To generate serum growth medium (SGM), human serum (Rockland Pharmaceuticals, 398
Limerick, PA) was thawed on ice and diluted in Dulbecco's modified Eagle's medium 399 (DMEM, VWR, Radnor, PA) to 40% (v/v). Bacteria were inoculated from frozen stocks 400 into 300 µL of SGM in Eppendorf tubes and incubated at 37 ˚C overnight without agitation. 401
After incubation, cells were diluted 10-fold into 450 µL of fresh SGM, followed by addition 402 of meropenem (10 µg/mL). Survival was measured by diluting and spot plating for cfu/mL 403 at the indicated times. For recovery time-lapse images, cells were concentrated 10-fold 404 ) and the pellets frozen at -80˚C. After lysis by sonication, the protein was found to be 436 insoluble. Insoluble protein pellets were resolubilized in 3 M urea (VWR, Radnor, PA) and 437 purified using immobilized metal affinity chromatography using Ni-NTA resin (Qiagen, 438
Hilden, Germany). Eluted proteins were renatured by three-step dialysis to a final buffer 439 composition of 20 mM Tris, 150 mM NaCl, 50 µM ZnSO4 and 30% (v/v) glycerol. The 440 resulting protein was quantified by Bradford Assay (45) and its functionality verified in a 441 biological assay by purified NDM-1's ability to restore growth of meropenem-susceptible 442 E. coli MG1655 on agar containing meropenem (10 µg/mL). 724 µg/mL, 0.5 µg/mL, 1 µg/mL, 2 µg/mL, 4 µg/mL, etc.) are rounded up to the next upper two-fold value before categorization. Therefore, an MIC 725 value of 3 µg/mL would be rounded up to 4 µg/mL, and thus considered resistant using breakpoints for Enterobacteriaceae in the M100-S29 726 document.
727
f Data were interpreted using the Clinical and Laboratories Standards Institute M100-S29 and M45 documents.
728
g The isolate intersected the meropenem Etest strip between 24-32 µg/mL.
729
h There are no interpretative criteria for antibiotic susceptibility testing performed on BHI+ agar. Nonetheless, essential agreement between MHA
730
and BHI+ agar was 100% for all isolates except ARB0120. However, ARB0120 tested resistant to meropenem (≥4 µg/mL) on both media and in 731 agreement with data obtained by the ARB (>8 µg/mL).
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Klebsiella aerogenes WCM0001
Klebsiella pneumoniae WCM0001 
